July 27, 2021
On July 27th, ASBM Advisory Board Chair Philip Schneider presented an online Continuing Education (CE) course entitled the “The State of the Biosimilars Market in 2021”. The course was presented in conjunction with Long Island University College of Pharmacy (LIU-Pharmacy) and viewed by more than 150 pharmacists, mostly from the New York area. The presentation looked […]
July 12, 2021
On June 15th, the American Medical Association (AMA) passed a resolution opposing the practice of insurers providing financial incentives for patients to switch to a payer-preferred treatment. The resolution was drafted by the American Colloge of Rheumatology (ACR) and passed during the AMA’s June 2021 Special Meeting. The ACR drafted the resolution after learning Cigna was notifying patients […]
January 19, 2021
On January 19th, ASBM submitted comments on Draft Guidance issued November 19, 2020 by the FDA entitled “Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act” The document offers insights into how FDA will handle certain aspects of submissions and labeling for interchangeable biosimilars. These include how an applicant may seek FDA review for […]
December 1, 2020
On November 22nd and 29th, ASBM Executive Director Michael Reilly and Advisory Board Chair Philip Schneider presented to the Saudi Gastroenterology Association. The 45-minute presentation was livestreamed to gatherings of several hundred gastroenterologists in the three largest cities in Saudi Arabia: Riyadh, Jeddah, and Dammam. Entitled “Lessons from European Biosimilar Markets”, the presentation was based on […]
November 18, 2020
On November 15th, ASBM submitted comments on the United Kingdom’s Medicines and Healthcare products Regulatory Agency’s (MHRA’s) guidance intended to help developers of biosimilars more clearly understand the requirements for biosimilar products in the UK. The new guidance is based on current EMA biosimilar guidance, with additional details about: UK reference products the lack of requirement […]
June 15, 2020
During the month of June, ASBM will be participating in three virtual conferences. We encourage all our members to visit the websites of these virtual conferences. EULAR E-Congress (From June 3) ASBM will present a poster abstract entitled “European Prescribers’ Perspectives on Biosimilars”. Data is drawn from ASBM’s 2019 survey of Rheumatologists in France, Germany, Italy, […]
May 5, 2020
On April 27th, the journal Digesitve Diseases and Sciences published a editorial by Frank I. Scott, MD entitled “Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch?. Dr. Scott heads the Crohn’s and Colitis Center, Division of Gastroenterology and Hepatology, Department of Medicine, at the University of Colorado. In the editorial, Dr. Scott discusses a study appearing in the April issue […]
October 28, 2019
The undisputed leader in biosimilars with more than 60 products approved and the largest biosimilar market in the world, Europe has achieved impressive biosimilar uptake rates. These can be as high as 91% for older products (before the approval of the first monoclonal antibody biosimilar in 2013) and up to 43% for newer products (approved […]
June 6, 2019
ARLINGTON, Va., June 6, 2019 /PRNewswire/ — On May 27th, the Government of British Columbia (B.C.) announced a policy that will forcibly switch thousands of patients with serious, chronic conditions from their current biologic medicines to lower-cost “biosimilar” treatments, effective November 25th, 2019. The roughly 23,000 patients who will be affected include those with rheumatoid arthritis, plaque psoriasis, […]
May 1, 2019
newsletter | April 2019 issue 77 Who We Are The Alliance for Safe Biologic Medicines is an organization composed of patients, physicians, pharmacists, biotechnology companies that develop innovative and biosimilar medicines, and others who are working together to ensure that patient safety is at the forefront of the biosimilars policy discussion. It […]
